» Articles » PMID: 26318166

PDK1 Induces JunB, EMT, Cell Migration and Invasion in Human Gallbladder Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Aug 31
PMID 26318166
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The protein 3-phosphoinositide-dependent protein kinase 1 (PDK1) is upregulated in cancer. Here we showed that PDK1 stimulated cell proliferation, invasion and metastasis in gallbladder cancer (GBC), by inducing JunB and epithelial-mesenchymal transition. JunB levels were increased in GBC samples and positively correlated with PDK1 levels in tumors. High levels of JunB predicted poor overall survival in GBC patients. Thus, PDK1 functions as a tumor promoter in human GBC by upregulating JunB.

Citing Articles

Decoding dysregulated angiogenesis in HTLV-1 asymptomatic carriers compared to healthy individuals.

Letafati A, Mozhgani S, Marjani A, Amiri A, Siami Z, Mohammaditabar M Med Oncol. 2023; 40(11):317.

PMID: 37792095 DOI: 10.1007/s12032-023-02177-5.


Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients.

Roumeliotou A, Pantazaka E, Xagara A, Dimitrakopoulos F, Koutras A, Christopoulou A Cancers (Basel). 2023; 15(1).

PMID: 36612166 PMC: 9818148. DOI: 10.3390/cancers15010171.


PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.

Pai S, Yadav V, Kuo K, Pikatan N, Lin C, Chien M Int J Mol Sci. 2021; 22(21).

PMID: 34768921 PMC: 8584253. DOI: 10.3390/ijms222111492.


Possible involvement of the Hedgehog and PDPK1-Akt pathways in the growth and migration of small-cell lung cancer.

Tang N, Hu B, Zhang Y, Chen Z, Yu R J Int Med Res. 2021; 49(5):3000605211016562.

PMID: 34038205 PMC: 8161885. DOI: 10.1177/03000605211016562.


Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications.

Wang X, Shen X, Yan Y, Li H Biosci Rep. 2021; 41(4).

PMID: 33739396 PMC: 8026821. DOI: 10.1042/BSR20204402.


References
1.
Bhola N, Freilino M, Joyce S, Sen M, Thomas S, Sahu A . Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012; 11(6):1236-46. PMC: 3413198. DOI: 10.1158/1535-7163.MCT-11-0936. View

2.
Bayascas J, Leslie N, Parsons R, Fleming S, Alessi D . Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol. 2005; 15(20):1839-46. DOI: 10.1016/j.cub.2005.08.066. View

3.
Hueman M, Vollmer Jr C, Pawlik T . Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol. 2009; 16(8):2101-15. DOI: 10.1245/s10434-009-0538-x. View

4.
Mende I, Malstrom S, Tsichlis P, Vogt P, Aoki M . Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene. 2001; 20(32):4419-23. DOI: 10.1038/sj.onc.1204486. View

5.
Wu Y, Chang T, Huang Y, Chen C, Chou C . COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget. 2015; 6(27):23748-63. PMC: 4695149. DOI: 10.18632/oncotarget.4250. View